Deal Making

Featured on Deal Making

J&J boosts autoimmune disease pipeline with $6.5bn Momenta buy
Deal-Making
J&J boosts autoimmune disease pipeline with $6.5bn Momenta buyJ&J boosts autoimmune disease pipeline with $6.5bn Momenta buy

Johnson & Johnson is acquiring Momenta in a $6.5 billion deal that brings a slate of experimental autoimmune disease therapies.

More from Deal Making

Subscribe to receive our monthly print or digital publication
Join our 70,000+ readers. And yes, it's completely free.